Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
暂无分享,去创建一个
G. Morgan | W. Gregory | M. Drayson | F. Davies | G. Cook | G. Jackson | D. Cairns | J. Child | R. Owen | S. Bell | Kara-Louise Royle | G. Jackson
[1] M. Büchler,et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.
[2] S. Leyvraz,et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide , 2015, Haematologica.
[3] A. Waage,et al. Health-related quality of life in patients with multiple myeloma - does it matter? , 2015, Haematologica.
[4] L. Coates,et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial , 2014, The Lancet.
[5] M. Dimopoulos,et al. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial , 2013, Leukemia & lymphoma.
[6] Carlos Caldas,et al. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub‐types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial , 2013, International journal of cancer.
[7] G. Morgan,et al. Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment , 2013, Clinical Cancer Research.
[8] D. Esseltine,et al. Health‐related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial , 2012, European journal of haematology.
[9] G. Morgan,et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. , 2012, Blood.
[10] G. Morgan,et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results , 2012, Haematologica.
[11] G. Morgan,et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. , 2012, Blood.
[12] G. Morgan,et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. , 2011, Blood.
[13] P. Sonneveld,et al. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial , 2011, Annals of Hematology.
[14] I. White,et al. Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.
[15] G. Morgan,et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.
[16] P. Fayers,et al. What changes in health‐related quality of life matter to multiple myeloma patients? A prospective study * , 2010, European journal of haematology.
[17] R. Hájek,et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. , 2007, European journal of cancer.
[18] S. Kaasa,et al. Development of an EORTC questionnaire module to be used in health‐related quality‐of‐life assessment for patients with multiple myeloma , 1999, British journal of haematology.
[19] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[20] Lena Osterhagen,et al. Multiple Imputation For Nonresponse In Surveys , 2016 .
[21] P. Fayers,et al. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Austin,et al. About the authors , 2004, Artificial Intelligence Review.
[23] D. Osoba,et al. Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.